
    business objective change, no safety or efficacy concerns
  
['geographic atrophy', 'age related macular degeneration']
['ionis-fb-lrx', 'placebo (sterline saline 0.9%)']

        Key Inclusion Criteria:

          1. Must have given written informed consent and be able to comply with study requirements

          2. Females must be non-pregnant and non-lactating, and either surgically sterile or
             post-menopausal. Males must be surgically sterile or, if engaged in sexual relations
             with a female of child bearing potential, the subject must be using an acceptable
             contraceptive method from the time of signing the informed consent form until at least
             a period of 13 weeks after the last dose of Study Drug (ISIS 696844 or placebo)

          3. Well-demarcated Geographic Atrophy due to Age Related Macular Degeneration

        Key Exclusion Criteria:

          1. Clinically-significant abnormalities in medical history

          2. Diagnosis of primary or secondary immunodeficiencies of B lymphocyte function,
             splenectomy, glomerulonephritis or history of recurrent meningococcal disease

          3. Diabetes mellitus or thyroid disease unless well controlled for a period of at least 3
             months

          4. Clinically-significant abnormalities in screening laboratory values

          5. Unwillingness to be administered, or history of a serious reaction to protocol
             required vaccines

          6. Known history of or positive test for human immunodeficiency virus (HIV), hepatitis C
             or chronic hepatitis B

          7. History or presence of a disease other than AMD in study eye
      